45 results about "Narcotic Effects" patented technology

The invention relates to a preparation method of ropivacaine mesylate injection packed by a soda-lime glass bottle, which comprises the following processing steps of ingredient preparation, liquor preparation, soda-lime glass bottle and rubber plug cleaning, filling, capping, sterilization, lamp test, labeling, packing and finished product inspection. The injection is subject to a filtration sterilization processing step once and a flowing steam sterilization processing step once, wherein microorganisms larger than 0.22 microns in liquid medicine are removed by a filter method, microorganismssmaller than 0.22 microns are killed by flowing steam sterilization, and insoluble particles in the liquid medicine are removed during filtration sterilization simultaneously, thereby greatly reducingthe occurrence of phlebitis; and the invention is packed by the soda-lime glass bottle which has the advantages of heat resistance, acid and alkali resistance, large strength, and the like, thereby ensuring the stability of the medicine. Clinic comparison tests show that the ropivacaine mesylate injection packed by a soda-lime glass bottle has the advantages of quicker effect, long action time, reliable anesthetic effect, small toxicity to heart, separate blocking pf sensory and motor nerves, and the like, thereby being suitable for anesthesia in surgeries and postoperative analgesia.

The invention relates to an N-substituted imidazolecarboxylic acid ester chiral compound containing an ether side chain, a preparation method and an application thereof. The structure of the compound is shown in the formula (I). The compound can produce rapid and reversible general anesthesia effect. Animal experiments show rapid and short-acting pharmacological characteristics of the compound, so that the compound can be used as a rapid and short-acting general anesthesia medicine, meanwhile, compared with etomidate, the compound can reduce the inhibition effect on synthesis of adrenal cortical hormone, recovery is rapid and thorough, and the compound has obvious advantages and good application prospect. The only chiral carbon in the structure of the compound must be of R type. An imidazole ring in the structure of the compound has acidifiable N atoms, so that the compound and medicinal salt molecules thereof can be applied to the preparation of central inhibitory medicines which can produce sedative and hypnotic and/or anesthetic effects on animals or persons through veins or paths outside veins.

The invention discloses a quaternary ammonium salt compound as well as a preparation method and application thereof, and belongs to the field of chemical medicines. The present invention provides a compound represented by a formula I, or a pharmaceutically acceptable salt, a stereoisomer, a solvate, a prodrug, or a metabolite thereof. The compound takes effect fast, a long-time local anesthesia effect is achieved after single administration, the sensory nerve blocking time is longer than the motor nerve blocking time, the long-acting local anesthetic effect and the selective local anesthetic effect are achieved, and meanwhile, the side effect of the quaternary ammonium salt compound with the structural characteristics of a surfactant is obviously reduced. The compound has high safety, namely, the compound shown in the formula I and the pharmaceutically acceptable salt thereof can be used for preparing safe medicines with long-time local anesthesia and selective local anesthesia effects. The compound has the advantages of long local anesthesia action time, good local anesthesia selectivity and high safety.

A method for controlling a narcotic effect value of a mixture of at least two narcotic agents of a breathing gas is disclosed herein. The method includes setting a target value for a desired narcotic effect of narcotic agents and measuring a breathing gas concentration of each narcotic agent of the breathing gas. The method also includes converting measured breathing gas concentration of each narcotic agent to a narcotic effect value of the breathing gas and calculating a total narcotic effect value of the mixture of the at least two narcotic agents. The method also includes comparing the total narcotic effect value with the target value and determining whether or not to change the breathing gas concentration to meet the target value.

The invention discloses a compound shown as formula I in the specification, or a stereoisomer, or a pharmaceutically acceptable salt, or a solvate, or a prodrug, or a metabolite, or a deuterated derivative thereof. Belonging to the field of pharmaceutical chemistry, the compound is a polysubstituted triazole formate derivative with a novel structure. The invention also discloses application of thepolysubstituted triazole formate derivative in preparation of drugs with sedative, hypnotic and/or anesthetic effects, and application in preparation of drugs capable of controlling status epilepticus. The compound has good inhibition effect on the central nervous system, and provides a new choice for clinical screening and/or preparation of drugs with sedative, hypnotic and/or anesthetic effectsand status epilepticus controlling function.

The invention discloses a compound shown in a formula I, or a stereoisomer, or a pharmaceutically acceptable salt, or a solvate, or a prodrug, or a metabolite, or a deuterated derivative of the compound, and belongs to the field of medicinal chemistry. The compound is a substituted imidazolecarboxylate derivative with novel structure. The invention further discloses application of the substitutedimidazolecarboxylate derivative in preparation of drugs with effects of sedation, hypnosis and/or anesthesia and application of the substituted imidazolecarboxylate derivative in preparation of drugscapable of controlling status epilepticus, wherein the compound has good inhibition effects on the central nervous system, and a new choice is provided for clinically screening and/or preparing drugswith effects of sedation, hypnosis and/or anesthesia and drugs for controlling the status epilepticus.

The invention relates to the field of medicines, and particularly relates to a pharmaceutical composition which has anesthetic action in operation. The composition is prepared from 1.0-3.0mg of bupivacaine, 1-5mu g of sufentanil, 15-30mu g of tetrahydropalmatine, 15-30 mu g of indometacin and 0.1-0.5mg of ropivacaine. The anesthetic composition is preferably prepared from 3.0mg of bupivacaine, 3mu g of sufentanil, 20mu g of tetrahydropalmatine, 20mu g of indometacin and 0.3mg of ropivacaine.

A compound is shown in formula I and can be in the form of a pharmaceutically acceptable salt, or a stereoisomer, or a solvate, or a prodrug, or a metabolite. The compound takes effect rapidly and has a long-time local anesthetic effect following a single dose, with the sensory nerve blocking time being greater than the motor nerve blocking time, has both a long-acting local anesthetic effect and a selective local anesthetic effect, significantly reduces side effects of the compositions QX314 and QX314 and a quaternary ammonium salt compound with surfactant structural characteristics, and is safer. The compound of formula I of the present invention and a pharmaceutically acceptable salt thereof can be used for preparing drugs that have a long-time local anesthetic effect and a selective local anesthetic effect.

Disclosed are a propofol hydroxy acid ester compound with an ester constitutional terminal, a preparation method for the same and application thereof. As shown in the constitutional formula (I) of the compound, Y refers to a C1-4 linear carbon chain, and R refers to acetyl or propiono. The propofol hydroxy acid ester compound can be prepared by utilizing corresponding propofol hydroxy acid ester as raw materials and is obtained by means of esterification reaction with corresponding acid anhydride. As experiments show, the compound is stable in vitro but capable of quickly releasing propofol with sedation and hypnogenesis and/or narcotism in blood plasma. Since hydroxy in propofol hydroxy butyric ester molecules is protected by means of shielding, heat stability of the propofol hydroxy acid ester compound is improved, and self-decomposition of the propofol hydroxy acid ester compound caused by lactonization is reduced.

The invention discloses an alkyl-substituted phenol carboxylate derivative, and a preparation method and application thereof. The structure of the derivative is shown in the specification, wherein X in a formula is O, S and NR, and R is H or C1-5 alkyl; Y is CH2, CH2CH2 or CO; Z is OH, NH2, HSO4, H2PO4, N (CH3) 2, NHCH3, N < + > (CH3) 3, H2NPO3, OCH2COOH or H2NMePO3; L is isopropyl or A pharmaceutically acceptable salt of the alkyl-substituted phenol carboxylate derivative, such as sodium salt, amino acid salt, hydrochloride and the like. The invention also discloses a pharmaceutically acceptable solvate, such as a hydrate. The compound represented by formula (I) and the pharmaceutically acceptable salt or solvate thereof may have water solubility, are stable in aqueous solution, can rapidly release alkyl substituted phenol and non-toxic and low-toxicity metabolites with sedative-hypnotic and/or anesthetic effects under the action of enzyme after entering body, and are good in safety,so that the compound can be applied to the field of sedative-hypnotic and/or anesthetic drugs for intravenous or extravenous administration.

A compound is shown in formula (I). The derivatives of the compound include a stereoisomer, a pharmaceutically acceptable salt, a solvate, a prodrug, a metabolite, a deuterated derivative. The compound is a structurally novel substituted imidazole formate derivative. Substituted imidazole formate derivatives are used in preparing a drug with sedative, hypnotic and/or anesthetic effects, as well as a drug that can control the state of epilepsy. The compound has a good inhibitory effect on the central nervous system, and provides a new option for clinical screening of and/or preparation of a drug with sedative, hypnotic and/or anesthetic effects and controlling the state of epilepsy.

The invention discloses a preoperative narcotic drug and a preparation method thereof, and belongs to the field of traditional Chinese medicines. Raw materials of effective components of the drug comprise cow pea pod, honey mushroom, cinnamomum bodinieri, adiantum capillus veneris, trigonotis peduncularis, lotus seeds, kweichow sage herb, java marsh pennywort, denseflower bulbophyllum herb, valerian, platycladi seeds, citronella, tubeflower dutchmanspipe roots, ants, acorus calamus and decumbent corydalis tuber. Selected medicinal materials are suitable in compatibility and complement each other, are combined to achieve the functions of easing pain, nourishing heart, calming endogenous wind, calming liver, dispelling wind, dredging collaterals, regulating qi, relieving pain, calming nerves and strengthening tendons and bones and can directly reach narcotic portions. The drug has remarkable narcotic effects in clinical operative treatment and has the advantages that the drug is an ideal narcotic product and rapid in effect, safe, convenient, free from toxic and side effects, low in price and easy to prepare.

The invention discloses a ketone-substituted heterocyclic compound and an anesthetic effect thereof. Specifically provided are a compound represented by formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a deuterated derivative thereof. The ketone-substituted heterocyclic compound provided by the invention has a good central nervous system inhibition effect, can generate sedative, hypnotic and/or general anesthesia effects, and can control the epilepsy persistent state; the ketone-substituted heterocyclic compound also has the characteristics of quick response and quick recovery while maintaining excellent anesthetic activity; meanwhile, the ketone-substituted heterocyclic compound has almost no inhibition effect on the adrenal cortex function, has small side effects, solves the technical problems in the field, and provides a new choice for clinically screening and/or preparing sedative, hypnotic and/or general anesthesia medicines and medicines forcontrolling the epilepsy persistent state.